Search by Categories
- Insights
- Rare Disease
- Oncology
- Cell and Gene Therapy
- Medical Devices
- Consulting
- News & Analysis
-
Therapeutic Areas
Our expertise in the industry
The US FDA has recently granted Orphan Drug Designation to AstraZeneca’s Imfinzi (durvalumab) and tremelimumab, combination therapy for HCC. Imfinzi, a monoclonal antibody, binds and inhibits the interaction of PD-L1 with PD-1 and CD80. The drug blocks tumour’s immune-evading mechanism and releases the inhibiti...
Find More-Agonist.png "Toll-like Receptors Agonist")
The American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.
